louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03211728: Does Perioperative Pregabalin Reduce Postoperative Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction Surgery Under Spinal Anesthesia?
Official title: Does Perioperative Pregabalin Reduce Postoperative Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction Surgery Under Spinal Anesthesia?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anterior Cruciate Ligament (ACL) Reconstruction
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2017-07-07
Enrollment: 96
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Candidate for arthroscopic ACL reconstruction are divided into two groups of pregabalin and placebo with 48 patients in each group. The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose and a placebo is administered in control group.
Primary purpose: PREVENTION

Brief summary: The investigators hypothesize that perioperative oral administration of pregabalin would reduce postoperative pain and produce reduction in postoperative opioid consumption after anterior cruciate ligament (ACL) reconstruction . Patients are randomly assign to 1 of 2 groups. The placebo group receive placebo capsules 1 hour before surgery and 12 hours after initial dose. The pregabalin group receive pregabalin 150 mg, respectively at the same points.


Eligibility criteria: Inclusion Criteria:

* age between 20-65 years
* physical condition type I or II in ASA (American Society of Anesthesiology)

Exclusion Criteria:

* patients of ASA classification 3 or more
* with a history of cardiovascular or respiratory disease
* dizziness or frequent headache
* active alcohol or drug usage,
* intake of any analgesics daily or 48 hours before surgery
* impaired renal and/or hepatic function

Primary outcomes:
measure: Postoperative pain scores
timeFrame: 12 hours after surgery
measure: Postoperative pain scores
timeFrame: 24 hours after surgery
measure: Postoperative pain scores
timeFrame: 36 hours after surgery
measure: Postoperative pain scores
timeFrame: 2 weeks after surgery
Secondary outcomes:
measure: Opioid consumption
timeFrame: the first 48 hours after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine
Study officials:
References:
Clinical trial NCT05221528: Association Between Lipid Profiles and Cardiovascular Events
Official title: Study on the Association Between Lipid Profiles and Cardiovascular Events: Analysis From the Korean Nationwide Health Insurance Database
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dyslipidemias
Cardiovascular Diseases
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2022-02-03
Enrollment: 4234339
Sex: ALL
Minimum age (years): 30
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects (age 30-74 years) who underwent general health check-ups in 2009

Brief summary: KORLIPID (Study on the Association between Lipid Profiles and Cardiovascular Events) registry enrolled 4234339 subjects who underwent general health check-ups provided by National Health Insurance Service in 2009.

Detailed description: Subjects who underwent general health check-ups provided by National Health Insurance Service in 2009 were included in KORLIPID study. Demographic data, anthropometric data and medical information from general health check-ups were collected. In addition, medical records in National Health Insurance Service between 2002 and 2018 were also collected.

Eligibility criteria: Inclusion Criteria:

* Subjects who underwent general health check-ups in 2009

Exclusion Criteria:

* Age less than 30 years
* Age 75 years or more

Primary outcomes:
measure: Myocardial infarction
timeFrame: until 2018 after inclusion
Secondary outcomes:
measure: Stroke
timeFrame: until 2018 after inclusion
measure: Heart failure
timeFrame: until 2018 after inclusion
measure: Death
timeFrame: until 2018 after inclusion
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT03528928: Viewing Surface Electrical Stimulation on Pelvic Floor With Ultrasound
Official title: Evaluation of Pelvic Floor Muscle With Surface Electrical Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelvic Floor Disorders
Keywords: pelvic floor
electrical stimulation
bladder
ultrasound
Lead sponsor: Elidah, Inc.
Sponsor class: INDUSTRY
First posted: 2018-05-18
Enrollment: 8
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: Surface electrical stimulation, Elitone by Elidah, Inc.
Primary purpose: OTHER

Brief summary: Subjects will place a surface electrode on their perineal area after a bladder-filling protocol. Transabdominal ultrasound will image the base of the bladder at rest, voluntary pelvic floor contraction, with the surface electrical stimulation and with a combined pelvic floor contraction and electrical stimulation active.


Eligibility criteria: Inclusion Criteria:

* Age:18-80y
* Gender: female

Exclusion Criteria:

* Moderate-severe stress incontinence\*: As determined by self-reported \>3 accidents in 24-hr period
* Currently pregnant, may be pregnant (Unsure pre and peri-menopausal women should take a pregnancy test.)
* Active urinary tract infection (UTI)
* Pelvic pain, Painful bladder syndrome, underlying neurologic/neuromuscular disorder that may impact ability to partake in the trial
* implanted cardiac device or untreated cardiac arrhythmia
* Obesity as defined by BMI \>= 30 (height, weight recorded)
* Anyone with impaired decision making, drug or alcohol dependence, or potentially suicidal.
* Anyone who lacks the capacity to consent for themselves or who requires a legal representative to give informed consent \* Stress urinary incontinence: as determined by an answer of "Yes" to a standard question (from King's Health Questionnaire): "Do you lose urine with physical activities such as coughing, sneezing, running?"

Primary outcomes:
measure: Movement of the Bladder
timeFrame: 1 Day
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Wayne
country: United States
facility: Wome's Health Advantage
state: Indiana
Study officials:
References:
Clinical trial NCT00722228: Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Colorectal Cancer
Ovarian Cancer
Gastric Cancer
Breast Cancer
Lung Cancer
Kidney Cancer
Melanoma
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2008-07-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric, ovarian, breast, lung and kidney epithelial cancer. Tumor cells grown in the laboratory will be modified to make them stimulatory to the immune system, irradiated to kill them, and injected to the patient eight times at two-week intervals. This protocol is expected to prolong survival of metastatic cancer patients.


Eligibility criteria: Inclusion Criteria:

* One of the following metastatic cancers: Melanoma, breast, ovary, colorectal, gastric, lung or kidney
* Above 18 years of age
* Failure of at least one chemotherapy protocol
* Clinical performance status of ECOG 0,1
* Absolute neutrophil count greater than 1000/mm3
* Serum ALT/AST less than three times the upper limit of normal
* Serum creatinine less than or equal to 1.6 mg/dl.
* Must be able to understand and sign the Informed Consent document

Exclusion Criteria:

* Below 18 years of age
* Women who are pregnant
* Life expectancy of less than three months

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
References:
Clinical trial NCT07022028: Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis
Official title: Ventilator Weaning Practices in Patients Intubated for Guillain-Barré Syndrome or Myasthenia Gravis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myasthenia Gravis
Guillain-Barre Syndrome
Keywords: Myasthenia Gravis
Guillain-Barre syndrome
Ventilator Weaning
Airway Extubation
Intensive Care Unit
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2025-06-15
Enrollment: 800
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients intubated and mechanically ventilated in ICUs for Guillain-Barré syndrome or myasthenia gravis

Brief summary: Guillain-Barré syndrome and myasthenia gravis are two neuromuscular diseases that are commonly managed in ICUs that may require different weaning protocols. To date, no study has compared weaning modalities from mechanical ventilation in patients with these two diseases. Our objective was to assess and compare for ventilator weaning modalities between patients mechanically ventilated for Guillain-Barré syndrome or for myasthenia gravis in a large-scale multicenter study.


Eligibility criteria: Inclusion Criteria: All patients mechanically ventilated for at least 48 hours for Guillain-Barré syndrome or myasthenia gravis -

Exclusion Criteria: Patients mechanically ventilated less than 48h or intubated for another reason than the neuromuscular disease.

-

Primary outcomes:
measure: The proportion of patients with prolonged weaning
timeFrame: 7 days after the initial separation attempt from the ventilator
Secondary outcomes:
Other outcomes:
Locations:
city: Poitiers
country: France
facility: CHU de POITIERS
Study officials:
affiliation: University Hospital of Poitiers
name: Arnaud W THILLE, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01108328: Evaluation of Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX)
Official title: A Prospective, Single Crossover, Randomized, Double Blind Placebo Controlled Trial Evaluating Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX) vs. Rice Flour Control, in Overweight and Moderately Obese Females.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Appetite and Hunger, Suppression
Blood Glucose, Postprandial
Keywords: viscous
fibre
polysaccharide
blood glucose
postprandial
appetite
hunger
satiety
Lead sponsor: Canadian Center for Functional Medicine
Sponsor class: OTHER
Collaborators: name: University of British Columbia
name: InovoBiologic Inc.
First posted: 2010-04-22
Enrollment: 35
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of the study is to compare subjective appetite ratings and after-meal and 24 hour blood glucose levels within overweight and obese female subjects consuming either a standardized 3 day low calorie diet supplemented with a viscous fibre known as PGX (treatment) or a rice flour (placebo control). Each treatment phase will be 3 days in length and separated by 3 week washout phase, so subjects will also be acting as their own control. Subjects will be randomized to either start with the low calorie diet with PGX or the low calorie diet supplemented with rice flour. We hypothesize that the 3 day LCD with PGX will elicit an improved appetite score compared to the 3 day LCD supplemented with the rice flour placebo control.


Eligibility criteria: Inclusion Criteria:

- BMI 25-35 Kg/m2

Exclusion Criteria:

* Known diabetes
* Medications or natural health products that affect appetite
* Contraindications to LCD
* Any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the protocol.

Primary outcomes:
measure: Change in the ratings of the variables in the Appetite Visual Analog Scale and the overall Appetite Score.
timeFrame: 3 days
Secondary outcomes:
measure: Changes in 2-hour postprandial areas under the curve (AUC) and 24 hour blood glucose (CGMS) profiles.
timeFrame: 3 days
Other outcomes:
Locations:
city: Coquitlam
country: Canada
facility: Canadian Centre for Functional Medicine
state: British Columbia
city: Coquitlam
country: Canada
facility: Canadian Center for Functional Medicine
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Michael Lyon, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kacinik V, Lyon M, Purnama M, Reimer RA, Gahler R, Green TJ, Wood S. Effect of PGX, a novel functional fibre supplement, on subjective ratings of appetite in overweight and obese women consuming a 3-day structured, low-calorie diet. Nutr Diabetes. 2011 Dec 12;1(12):e22. doi: 10.1038/nutd.2011.18.
Clinical trial NCT00523328: BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)
Official title: An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects With Rheumatoid Arthritis Who Previously Participated in Study 104RA203
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid Arthritis
Arthritis
BG9924
methotrexate
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2007-08-31
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to observe the long-term treatment of BG9924

Detailed description: Extension study for 104RA203 (NCT 00458861)

Eligibility criteria: Inclusion Criteria:

* Must be a participant from Study 104RA203 (NCT 00458861)

Exclusion Criteria:

* Participants with a significant change in medical history from their previous BG9924 Study 104RA203 (NCT 00458861).
* Nursing mothers, pregnant women, or women who are planning to become pregnant while in the study.
* Male and female participants of child-bearing potential not willing to practice effective birth control for the duration of the study.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Primary outcomes:
measure: To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.
timeFrame: The duration of this study is 18 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Coordinating Research Site
state: California
city: Liège
country: Belgium
facility: Coordinating Research Site
city: Toronto
country: Canada
facility: Coordinating Research Site
state: Ontario
city: Newcastle
country: United Kingdom
facility: Coordinating Research Site
Study officials:
affiliation: Biogen
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01121328: Autologous Umbilical Cord Blood Transfusion for Preterm Neonates
Official title: Autologous Umbilical Cord Blood Transfusion for Preterm and Low Birth Weight Neonates: A Pilot Feasibility Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Prematurity
Respiratory Distress Syndrome
Anemia of Prematurity
Intraventricular Hemorrhage
Keywords: Preterm neonates.
Autologous cord blood transfusion.
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2010-05-12
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Maximum age (years): 30
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a pilot study to test feasibility of collection, preparation and infusion of a baby's own (autologous) umbilical cord blood in the first 14 days after birth if the baby is born premature \<35 weeks of gestation.

Detailed description: In Egypt, 12-15.8% of live neonates are low birth weight and it is estimated that about one third of such infants are preterm \[1\] (UNICEF, 2001). In a study that Campbell et al. (2004) conducted in Egypt, the neonatal mortality rate was estimated to be 25 per 1000 live births. prematurity was considered the main cause of neonatal deaths (39%), followed by asphyxia (18%), infection (7%), especially in the late neonatal period, and congenital malformations (6%). A substantial proportion (29%) could not be classified \[2\]. In developing countries, prematurity was the main cause of early neonatal deaths (62%)\[3\] Autologous cord blood transfusion will be safe, and cheap. The preterm neonates need transfusion of whole blood or any of its components at a time during NICU admission.

Eligibility criteria: Inclusion Criteria:

* Preterm neonates less than 34 weeks of gestation.
* Low birth weight less than 1500 grams

Exclusion Criteria:

* Congenital malformations.
* Suspected inborn error of metabolism.
* Suspected inherited neurologic disease.

Primary outcomes:
measure: Duration of mechanical ventilation
timeFrame: 30 days
Secondary outcomes:
measure: Survival
timeFrame: 18 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Children's Hospital, Faculty of Medicine, Ain Shams University
Study officials:
affiliation: Children's Hospital, Faculty of Medicine, Ain Shams University
name: Prof. Sahar MA Hassanein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06829628: A Mobile Chatbot with ARCS-V Motivation Theory on Learning Motivation
Official title: The Effects of Teaching Strategies Integrating a Mobile Chatbot with ARCS-V Motivation Theory on Learning Motivation and Performance in Medical-Surgical Nursing
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Nursing Education Research
Chatbot-Based Training
Lead sponsor: National Defense Medical Center, Taiwan
Sponsor class: OTHER
First posted: 2025-02-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 21
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study will implement a smartphone chatbot in medical-surgical nursing education to enhance nursing students' learning motivation and academic performance. T


Eligibility criteria: Inclusion Criteria:

* Second-year Nursing students
* Taking an adult nursing course
* Aged 18 or older
* Willing to voluntarily participate in this study

Exclusion Criteria:

* Students auditing the course

Primary outcomes:
measure: learning motivation
timeFrame: Baseline, 9 weeks, and 18 weeks after intervention
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03362528: Database and Calibration of a Non-invasive Glucose Monitoring Device
Official title: Database and Calibration of a Non-invasive Glucose Monitoring Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Lead sponsor: RSP Systems A/S
Sponsor class: INDUSTRY
First posted: 2017-12-05
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This clinical study has been launched to collect spectral raman data paired with validated glucose reference values in private homes of subjects.

Detailed description: Subjects will collect 2-4 daily optical raman readings paired with capillary Blood Glucose comparator in own home with maintaining usual routines. Subjects will either collect data for 30 days during a 60 days period or collect data for 90 days during 6 months.

Eligibility criteria: Inclusion Criteria:

* Male and female subjects 18 years of age or older
* Diabetic (all types) patients

Exclusion Criteria:

* Pregnant women
* Subjects not able to understand and read Danish
* In investigator's opinion, subject is not able to follow instructions as specified in the protocol
* Subjects not able to hold hand/arm steadily
* Extensive skin changes, tattoos or diseases on probe application site
* Rejection by prescreening optical measurements
* Known allergy to medical grade alcohol used to disinfect skin

Primary outcomes:
measure: Generation and validation of predictive algorithms for determining blood glucose levels
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Department of Endocrinology M
Study officials:
affiliation: Odense University Hospital, Dpt. of Endocrinology M
name: Jan Erik Henriksen, MD
role: PRINCIPAL_INVESTIGATOR
References: